Back

Patient Explorers

Regular users

Current states

I use multiple toxins. Dysport® provides good symptom relief, but it’s a bit trickier to use than Botox so I don’t use it for everyone

Desired states

Dysport® is the toxin I feel confident to use across all patient types (not just complex) as I believe it delivers optimal outcomes where there’s benefits for the patient experience

A.Raise HCP aspiration to achieve goals for more of their patients
B. Raise correlation between Dysport® symptom control achievement and dosing
C.Emphasize that Dysport® has broad applicability across eligible patient types which makes it the toxin of choice

target

Messaging should be straight to the point, without complexity, with a focus on practical aspects of using Dysport®

Communication objective associated: Raise HCP aspiration to achieve goals for more of their patients

  1. Achieve meaningful, patient-centered goals for a broader range of patients: ULIS III and AboLiSh show Dysport® delivers meaningful, patient-centered outcomes across a wide spectrum of adult spasticity cases
  2. Optimize outcomes by tailoring your approach cycle after cycle.
  3. Help more patients reach higher-level goals using advanced strategies: Leverage the flexibility of Dysport® tailor goals and injection plans to each patient’s evolving needs, supported by robust real-world evidence.

Key supportive study :

  • Upper limb ULIS III : Turner-Stokes L, et al. J Rehabil Med. 2021;53(1):jrm00133
  • Lower limb AboLish: Esquenazi A, et al. Arch Phys Med Rehabil. 2024

Key material:

  • CLM presentation
  • AboLiSh infographic
  • ULIS III infographic

Digital material for follow up:

  • VAE AboLish / ULIS III (to come)
  • VAE Goal setting (to come)
  • Goal setting podcast Jacinto
  • Goal setting video Jacinto

Communication objective associated: Raise correlation between Dysport® symptom control achievement and dosing

  1. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered9
  2. In ULIS‑III, real‑world upper‑limb cohorts showed significantly longer intervals between injections with Dysport® than with other BoNT‑As in upper limb spasticity
  3. AboLiSh (16‑month observational, LLS): effectiveness set mean reinjection interval ≈ 18.3 ± 6.1 weeks, with clinically meaningful cumulative goal gains over cycles—so routine practice also supports longer spacing in ambulatory LLS

Key supportive study:

  • High amount of neurotoxin: . Field M, et al. Toxins. 2018;10:535
  • ULIS III : Turner-Stokes L et al., J Rehabil Med. 2021;53(1):jrm00133
  • AboLiSh : Esquenazi A et al., Arch Phys Med Rehabil. 2024.

Key material:

  • CLM presentation

Digital material for follow up:

  • Esquenazi webinar
  • Jacinto reflection 
  • VAE on duration of response (to come)

Communication objective associated: Raise correlation between Dysport® symptom control achievement and dosing/injection technique

  1. Dysport® has a dose-response effect16
  2. Dysport® treatment can be tailored to suit each patient’s needs—optimizing dosing and injecting technique to create a better experience for the patient
  3. Recommended doses for upper/lower limb muscles

Key supportive study :

  • Upper limb : Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb : Gracies J, et al. Neurology. 2017;89(22):2245-2253
  • Abolish : Esquenazi A, et al. Arch Phys Med Rehabil. 2024

Key material:

  • CLM presentation
  • Dosing app
  • FIT guide

Digital material for follow up:

  • Ixcellence website – Echo modules

Communication objective associated: Emphasize that Dysport® has broad applicability across eligible patient types which makes it the toxin of choice

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation (slide 5,10,25,47)
  • Dosing app
  • Ixcellence website
  • FIT guide

Digital material for follow up

  • Invitation to (inter)national training
  • Dosing app guide (to come)